fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Investors Experience Wild Roller Coaster Ride This Week – $AAPL $INVO Rise!

By John F. Heerdink, Jr.
“Live life to the fullest, and focus on the positive.” – Matt Cameron, American Musician, Born: November 28, 1962


Happy Weekend All!

I hope all is well with you during this first week in December. As we speed towards the end of the year, the markets are becoming increasingly volatile as tax maneuvers persist, fear of the omicron variant ebbs and flows, & the Fed surprisingly has now changed its tune with Fed Chair Jerome Powell laying out his new ‘understanding’ this week that the Fed’s tapering of monthly bond purchases may need to occur earlier that they had previously expected & that inflation should no longer be referred to as “transitory.” It was wonderfully puzzling feeling this week for most and it disturbed the market pressuring it to the downside with every other day ending in the red & ultimately giving it an uncomfortable rickety old and worn out roller coaster coaster feel. 

We also received a number of macroeconomic reports. On Monday, the Pending Home Sales report for October confirmed a 7.5% rise. On Tuesday, the Conference Board’s Consumer Confidence Index report confirmed a move lower to 109.5 in November. The Chicago PMI report also confirmed a fall to 61.8 in November. The FHFA Housing Price Index report showed a rise to .9% M/M in September. The S&P Case-Shiller Home Price Index report confirmed a rise by 19.1% Y/Y in September. On Thursday, the November ISM Manufacturing Index report confirmed that it ticked up to 61.1 confirming expansion once again. The Total construction spending report confirmed a rise by .2% M/M in October, while the total private construction report showed a drop by .2% M/M, & total public construction spending rose by 1.8%. The ADP Employment Change report estimated that 534k jobs were added to private-sector payrolls in November. The final IHS Market Manufacturing PMI report for November came down at 58.3. The weekly MBA Mortgage Applications Index report showed a sharp 7.2% drop. On Friday, the November nonfarm payrolls report showed a rise by 210k & the October nonfarm payrolls were revised higher to 546k from 531k.  November private sector payrolls also moved up by 235k. October private sector payrolls were revised to 628k from 604k. September private sector payrolls were revised to 424k from 365k. The November unemployment rate was 4.2%. The U6 unemployment rate was lower 7.8%. November average hourly earnings rose .3%. The average workweek in November was 34.8 hours. Manufacturing workweek rose .1 hours to 40.4 hours. Factory overtime was unchanged at 3.2 hours. The labor force participation rate rose to 61.8% from 61.6%. The employment-population ratio moved up to 59.2% from 58.8% in October. The ISM Non-Manufacturing Index for November rose to a record high 69.1%. The IHS Markit Services PMI rose to 58 in the final reading for November. Factory orders for manufactured goods rise 1% M/M in October. Shipments of manufactured goods rose 2%.

As for the major indices this week, the S&P 500 closed at 4,538.43 (-1.2%), but remains up 20.8% YTD. 9 of the 11 sectors also finished the week in the red, with the communication services sector, the consumer discretionary sector, & the financials leading the downward move selling off over 2% this week. The 2 sectors that closed in the green were real estate and the utilities.  The Dow 30 held up the best closing at 34,580.08 (-.9%) & remains up 13% YTD. The Nasdaq also closed lower at 15085.47 (-2.6%) & is now 6.1% in 2 weeks, but remains up 17%. The small caps on the Russell 2000 also fell significantly again this week closing at 2,159.31 (-3.9%) and now down 8% in 2 week, but remain up 13.7% YTD. The MicroCaps also sold off sharply again this week as the iShares Micro-Cap ETF (IWC) closed at $135.62, off another -4.97% for the week & now off just shy of 15% over the last 3 weeks, but remains up 14.3% YTD. 

The yield curve’s volatility increased this week but saw the curve flatten overall as well with the 10-yr yield closed at 1.34%, down 15 basis points wk/wk and the 2-yr yield closed at .595%, up 8 basis points.

The U.S. Dollar Index also moved a little higher once again this week to end at 96.15 moving up from the 96.11 mark last week ending near a multi-year high once again. 

Next week, the macroeconomic schedule will serve the inflation, productivity and consumer credit reports.


EV, TECH, CONSUMER

Apple (AAPL) closed at $161.84, +3.21% over the last 5-days. On Nov. 23 Apple® filed a lawsuit against NSO Group and its parent company to hold it accountable for the surveillance and targeting of Apple users. The complaint provides new information on how NSO Group infected victims’ devices with its Pegasus spyware. To prevent further abuse and harm to its users, Apple is also seeking a permanent injunction to ban NSO Group from using any Apple software, services, or devices. NSO Group creates sophisticated, state-sponsored surveillance technology that allows its highly targeted spyware to surveil its victims. These attacks are only aimed at a very small number of users, and they impact people across multiple platforms, including iOS and Android. Researchers and journalists have publicly documented a history of this spyware being abused to target journalists, activists, dissidents, academics, and government officials.

EV giant Tesla (TSLA) moved higher to close at $1,014.97, -6.19% this week. Reportedly, Tesla CEO Elon Musk will be attending the company’s next earnings call.

Shares of Ford (F) closed at $19.14, -3.09% over the past 5-days. On December 2, Ford announced that “Our new products continue to roll, making Ford America’s best-selling automaker for the third consecutive month, a feat last accomplished in 1974. Ford was also the only major U.S. automaker to beat year ago sales results for November. On the strength of Mustang Mach-E, Ford delivered record electrified vehicle sales, growing more than three times faster than the overall segment. Retail sales were up 4.5 percent over a year ago, with SUVs having a best- ever November sales performance on record sales of our all-new Bronco family. We expect growth to continue, thanks to adding an additional 74,000 new vehicle orders in November.” – Andrew Frick, vice president, Ford Sales U.S. and Canada.

Snowflake (SNOW $345.11, -4.82%), the Data Cloud company, announced on Dec. 2 their financial results for its third quarter of fiscal 2022, ended October 31, 2021 and beat expectations. They reported Product revenue of $312.5 million, representing 110% year-over-year growth, that remaining performance obligations of $1.8 billion, representing 94% year-over-year growth, 5,416 total customers, Net revenue retention rate of 173%, 148 customers with trailing 12-month product revenue greater than $1 million.

Amazon.com, Inc. (NASDAQ: AMZN, $3,389.79, -3.27%. On Dec. 2, at AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, announced AWS Cloud WAN, a managed wide area network (WAN) service that makes it faster and easier for enterprises to build, manage, and monitor a unified global network that seamlessly connects cloud and on-premises environments. AWS Cloud WAN provides a central dashboard that enterprises can use to connect their on-premises branch offices, data centers, and Amazon Virtual Private Clouds (Amazon VPCs) across the AWS global network in just a few clicks. With AWS Cloud WAN, enterprises can get a complete view of their global network and use simple network policies to centrally configure and automate network management and security tasks. AWS Cloud WAN enables enterprises to use the AWS global network to provide a single unified network, which allows them to improve network health, performance, and security.


Shares of Microsoft Corp. (MSFT) closed at 323.01, -2.02% this week. This week, Microsoft’s CEO Satya Nadella reportedly sold nearly half of his holdings in the company for $285M and apparently it was for personal reasons. Maybe inflation was eating into his check account…

NVIDIA (NVDA) closed $306.93, -2.57% over the past 5-days.. Reportedly, the Federal Trade Commission has sued to block U.S. chip supplier Nvidia Corp.’s $40 billion acquisition of U.K. chip design provider Arm Ltd. Semiconductor chips power the computers and technologies that are essential to our modern economy and society. The proposed vertical deal would give one of the largest chip companies control over the computing technology and designs that rival firms rely on to develop their own competing chips. The FTC’s complaint alleges that the combined firm would have the means and incentive to stifle innovative next-generation technologies, including those used to run datacenters and driver-assistance systems in cars

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $93.53, -12.69% for the week and nearly 10% the last two weeks.

The Technology Select Sector SPDR Fund (XLK) closed at $165.13, -.52% for the week.

Disney (DIS) closed at $146.22, -1.28% for the week. According to U.S. data from mobile analytics company App Annie, Disney+ daily downloads rose more than 33% the weekend of the premiere (Nov 25- Nov 27) when compared to the daily average in the week prior (Nov 18-24.). On Dec. 1, The Walt Disney Company Board of Directors announced that it has elected Susan E. Arnold as Chairman of the Board, effective December 31, 2021. Ms. Arnold, a 14-year member of the Disney Board who has served as its independent Lead Director since 2018, will succeed Robert A. Iger as Chairman of the Board when he departs the Company at the end of the year.

Shares of McDonald’s (MCD) closed at $249.33, -.27% for the week. The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine announced this week that McDonald’s Corporation (NYSE: MCD) as a “Stock to Study”.

BIOTECH & HEALTHCARE

The Nasdaq Biotechnology ETF (IBB) closed at $148.39, -4.2% for the week, now down -2.05% YTD. The NYSE ARCA Biotech Index (^BTK) closed at 5,224.69, -1.93% for the week and is now down -8.96% YTD. In the other side of the coin or the smaller side of the biotech markets the SPDR S&P Biotech ETF (XBI) closed at $116.78, -6.21% for the week (over 14% the last 3 wks) and is off -22.2% for the year. The XBI’s 52-wk range is $108.71-$174.79.  The small stocks in this sector are definitely being hurt the most this year to say the least. 

On Nov. 30,  Atossa Therapeutics’ CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO presented at our sister organization Tribe Public’s FREE Webinar Presentation and Q&A Event. During this complimentary event, Atossa management addressed Q&A from the Tribe focused on Atossa’s research programs and future development. You can watch the event video titled “A Town Hall Q&A Event With Atossa Therapeutics Management Team” at the Tribe Public YouTube Channel by clicking here


Health Care Select Sector SPDR (XLV) moved up this week to close at $131.97, -1.35% over the last 5-days. 

GOLD & SILVER

Gold prices closed at $1,794, -$54 for the week & silver prices closed at $23.15, -$1.52/oz. for the week. Hecla Mining (HL) closed at $5.58, -9.27% for the week. First Majestic (AG) closed at $11.91, -10.32% for the week. 

MEMES REPORT

AMC Entertainment (AMC) closed at $29.01, -22.91% over the last 5-days. On Dec. 2, ReelWorks Studios and Fathom Events announce the release of their latest film THE MULLIGAN featuring Pat Boone (JOURNEY TO THE CENTER OF THE EARTH, STATE FAIR), Eric Close (“Nashville,” AMERICAN SNIPER, “Law & Order: Special Victims Unit”), Tanya Christiansen (I STILL BELIEVE, THE HATE U GIVE) and Charmin Lee (JUST MERCY, THE 5TH WAVE) with special appearances by American sportscaster Jim Nantz, Sports Commentator Jim Szoke, and PGA Champion Tom Lehman. THE MULLIGAN will be released in movie theaters nationwide spring of 2022. Fathom is a recognized leader in the entertainment industry as one of the top distributors of content to movie theaters in North America. Owned by AMC Entertainment Inc. (NYSE: AMC); Cinemark Holdings, Inc. (NYSE: CNK); and Regal Cinemas, a subsidiary of the Cineworld Group (LSE: CINE.L)., Fathom operates the largest cinema distribution network, delivering a wide variety of programming and experiences to cinema audiences in all of the top U.S. markets and to more than 45 countries.

GameStop (GME) closed at $172.39, -13.68% for the week.On Nov. 23, GameStop announced that it will report third quarter fiscal 2021 earnings results after the market closes on Wednesday, December 8, 2021. The Company will host an investor conference call at 5:00 pm ET on the same day to review its results. This call and all supplemental information can be accessed on GameStop’s investor relations website: https://investor.gamestop.com. The phone number for the investor conference call is 877-451-6152 and the confirmation code is 13725350. A recording of the conference call will be made available on the Company’s investor relations website.

Bed Bath & Beyond Inc. (NASDAQ: BBBY) announced announced recently that it expects to complete its $1 billion three-year share repurchase plan by the end of fiscal 2021 – two years ahead of schedule. Shares of BBBY closed at $17.86, -14.55% for the week. On Nov. 18, Bed Bath & Beyond officially announced the launch of H for Happy™, a new Owned Brand collection of holiday-inspired and seasonal celebratory goods that make it easy to turn everyday moments into life-long memories. Whether hanging stockings over the fireplace, setting a holiday table, lighting the menorah, or trimming a tree, H for Happy has everything needed to “home, happier™” this season and create celebratory moments all year long. Shares of BBBY closed at $23.25, +3.25% for the week. 

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $.8887, -3.4% for the week. On Dec. 2, Seanergy announced the delivery of a previously-announced Capesize vessel acquisition, M/V Dukeship (the “Vessel”), and the simultaneous commencement of its time charter (“T/C”) employment. In addition, the Company has successfully closed the previously-announced sustainability-linked loan facility with Piraeus Bank (the “Facility”).

BITCOIN

Bitcoin $BTC.X closed at $53,738.44, -7.04% this week.

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $55.14, -.79% over the last five days & +45.49% YTD. Oil prices fell 2.6% over the week, but remain up 36.8% YTD.

NEXT WEEK

The stock market will be back to a normal 5-day trading week next week.

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


  • Shares of INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $11.22, -15.83% this week. The 52-wk range is $7.28 – $30.37.
    • On Dec. 1,  INmune Bio announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK. Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, stated, “I’m delighted to have two of our team presenting our latest data on the mechanism of action of INKmune. These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK). Before this, mlNK cells could only be produced using multiple combinations of cytokines. These are the data which led us to the concept that INKmune is a ‘pseudokine’ that provides multiple signals to NK cells, akin to the multi-cytokine cocktails used by others. We also show that INKmune priming promotes significant proliferation of mlNK cells in vitro. These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS. At 119 days post first treatment, 60% of the patient’s NK cells showed the activated, tumor killing phenotype compared to fewer than 15% before INKmune therapy. The patient remains well and with a significantly improved ECOG status.”

    • Recently, INMB presented multiple poster presentations and a plenary talk at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that was held from November 9-12 in Boston. Learn more. 
    • The Maxim Group’s analyst Jason McCarthy confirmed his $42 Price target recently.  
    • On Nov. 3rd, INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” INmune Bio announced that they will deliver multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that is being held during November 9-12 in Boston. For details please visit the following link. 
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has been viewed over +30k times now to learn more.

    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.



  • Shares of InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed at $1.47, -12.50% this week.
    • Please visit the INM page at our website to learn more and check out the videos section too. The 52-wk range is $1.2545 – $8.94. 
    • On Nov. 29, InMed Pharmaceuticals (NASDAQ: INM) received a BUY Recommendation from Raghuram Selvaraju, Ph.D. a sell side analyst at H.C. Wainwright & CO. with a Price Target of $6. His report is titled “Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT”.  
  •  
    • On November 10, InMed announced their financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $48, -8.61% over the last 5-days. 
    • On Nov 4, FATE reported business highlights and financial results for the third quarter ended September 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December. We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted, CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $1.93, -15.35% this week. 
    • On Nov. 30,  Atossa Therapeutics’ CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO presented at our sister organization Tribe Public’s FREE Webinar Presentation and Q&A Event. During this complimentary event, Atossa management addressed Q&A from the Tribe focused on Atossa’s research programs and future development. You can watch the event video titled “A Town Hall Q&A Event With Atossa Therapeutics Management Team” at the Tribe Public YouTube Channel by clicking here
    • On Nov. 15, Atossa announced their financial results for the fiscal quarter ended September 30, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “Our progress in both the Endoxifen and COVID-19 programs, with our initiation of our trial in Australia for AT-H201, and our receipt of regulatory authorization in Sweden to commence an Endoxifen Phase 2 trial, have been key recent milestones, positioning us to move both of these programs forward and take the next steps toward developing therapies in urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value,” Review the balance of the story here. 
    • On October 23, Dr. Steven Quay CEO of Atossa Therapeutics (NASDAQ: ATOS) published an interesting and informative video called “Long COVID Is An important Issue.” You may view by clicking here now.
    • On September 30, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  •  

  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $2.95, +.34% this week.   
    • On Dec. 1, INVO Bioscience announced the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand. In April 2021, INVO Bioscience entered an exclusive distribution agreement with IVF Envimed Company Ltd. to distribute the INVOcell system within Thailand. Established in 1993, IVF Envimed Company Ltd. has established a wide network of clinics and hospitals across Thailand primarily focused on fertility solutions. IVF Envimed is a member of the ‘Thai Society of Reproductive Medicine’ which organizes congresses and educational programs where IVF Envimed participates. In November 2021, INVO Bioscience started to train physicians and embryologists from both private and government hospitals. In early 2022, INVO Bioscience and IVF Envimed will organize several ‘in person’ trainings in Bangkok with key fertility experts to supplement currently ongoing online trainings. INVO Bioscience is also planning to conduct a locally-based evaluation study to have localized data, a key element for both physicians and patients. “Following months of efforts and interactions with the governmental authorities in Thailand, we are thrilled to have received approval by FDA Thailand to commence commercialization of the INVOcell solution within Thailand,” commented, Steve Shum, CEO of INVO Bioscience. “Over the past number of months, we have been working closely with our partners at IVF Envimed to educate key opinion leaders within the country, including the recent training of several physicians and embryologists that should allow us to begin scaling up our commercialization efforts within the country. Further, we have identified physicians to help us with localized data collection on initial patients to assist in our longer term marketing efforts within the country. We look forward to working with Envimed and supporting their efforts to deliver the INVOcell solution in Thailand help address the underserved patient market in need of advanced reproductive treatment.”
    • On Nov 16, Colliers Secuirites issued an update report titled “Dedicated INVOcell Clinics To Begin Meaningful Sales in CY22. Decision On 5-Day label Expansion Expected in 1Q22.” The report carried a BUY rating on INVO and a Price Target of $6.
    • On Nov. 15, INVO announced their financial and operating results for the third quarter ended September 30, 2021, and provided a business update. Steve Shum CEO of INVO stated , “We continue to execute against our core mission of improving access to advanced fertility services for the many patients around the world through the use of the INVOcell solution. During the quarter, we achieved a significant milestone with the opening of our very first INVO Center, based in Birmingham, where we have commenced initial cycles. Further, we opened clinics in Atlanta, Georgia and Monterrey, Mexico to expand the INVO Center business model and we are working to open the San Francisco Bay Area clinic as soon as possible. We completed the acquisition of a Canadian-based entity that will be used to distribute the INVOcell in Canada and to develop INVO Centers in the region. With our INVO Center strategy now successfully underway, we are optimistic on the prospects for further expansion using this unique and innovative model. As part of a detailed review, we have initially identified more than 20 cities here in the U.S. that we believe have excellent characteristics in terms of demographics and level of current fertility care that would be ideal locations for an INVO Center.” READ the balance of the story here. 
    • On Nov. 8 after the market closed, INVO announced that it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.’s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022. Over the past three years, INVO has been executing on a multi-faceted commercialization strategy which includes partnering to open dedicated “INVO Centers” focused on INVOcell and the IVC procedure, and establishing agreements with distributors in key markets. The terms of the U.S. Distribution Agreement had limited the number of INVO Centers that we were allowed to operate. INVO can now further support U.S. fertility clinicians directly as the exclusive provider of INVOcell® in pursuit of our mission to bring advanced fertility care to the millions of people that are without access to treatment.
    • On October 20, INVO Bioscience, Inc. announced that four exciting poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland. “It’s extremely rewarding to see our technology highlighted at this year’s ASRM. Four independent abstracts were selected for presentation at the fertility industry’s most prominent annual meeting. On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,” stated Steve Shum, CEO of INVO Bioscience. LEARN MORE! 
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
      • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
      • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

INVO

    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.
    • On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Investing & Inspiration

  1. “If a man does not keep pace with his companions, perhaps it is because he hears a different drummer. Let him step to the music which he hears, however measured or far away.” – Henry David Thoreau
  2. “Adopting the right attitude can convert a negative stress into a positive one.” – Hans Selye
  3. “Money is something that keeps you alive and healthy and just keeps you focused. It’s the drive. It’s the passion.” – Travis Scott
  4. “Common sense is the collection of prejudices acquired by age eighteen.” – Albert Einstein
  5. “Live life to the fullest, and focus on the positive.” – Matt Cameron
  6. “You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln
  7. “However difficult life may seem, there is always something you can do and succeed at.”– Stephen Hawking
  8. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
  9. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  10. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  11. Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  12. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  13. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  14. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  15. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  16. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  17. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  18. “If opportunity doesn’t knock, build a door.” – Milton Berle
  19. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  20. “The smallest deed is better than the greatest intention.” – John Burroughs
  21. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  22. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  23. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  24. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  25. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  26. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  27. “Don’t go through life, grow through life.”– Eric Butterworth
  28. “This life is worth living, we can say, since it is what we make it.” – William James
  29. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  30. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  31. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  32. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  33. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  34. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  35. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  36. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  37. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  38. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  39. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  40. “One fails forward toward success.” – Charles Kettering
  41. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  42. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  43. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  44. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  45. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  46. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  47. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  48. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  49. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  50. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  51. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  52. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  53. “It takes a long time to grow an old friend.” – John Leonard
  54. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  55. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  56. “Man is only great when he acts from passion.” – Benjamin Disraeli
  57. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  58. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  59. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  60. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  61. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  62. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  63. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  64. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  65. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  66. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  67. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  68. “Every good painter paints what he is.” – Jackson Pollock
  69. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  70. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  71. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  72. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  73. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  74. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  75. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  76. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  77. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  78. “Eliminate emotion from your investment program.” -John C. Bogle

  79. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  80. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  81. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  82. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  83. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  84. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  85. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  86. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  87. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  88. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  89.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  90. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  91. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  92. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  93. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  94. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  95. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  96. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  97. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  98. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  99. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  100. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  101. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  102. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  103. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  104. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  105. “View health as an investment, not an expense.” – John Quelch

  106. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  107. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  108. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  109. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  110. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  111. “A problem is a chance for you to do your best.”–  Duke Ellington
  112. “The best way to predict the future is to create it.” -Peter Drucker
  113. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  114. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  115. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  116. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  117. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  118. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  119. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  120. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  121. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  122. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  123. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  124. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  125. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  126. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  127. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  128. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  129. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  130. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  131. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  132. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  133. “Modern medical advances have helped millions of people live longer, healthier lives.

  134. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  135. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  136. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  137. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  138. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  139. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  140. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  141. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  142. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  143. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  144. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  145. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  146. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  147. “Investment is most successful when it is most businesslike.” – Ben Graham

  148. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  149. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  150. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  151. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  152. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  153. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  154. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  155. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  156. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  157. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  158. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  159. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  160. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  161. “Know what you own, and know why you own it.” – Peter Lynch
  162. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  163. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  164. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  165. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  166. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  167. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  168. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  169. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  170. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  171. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  172. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  173. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  174. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  175. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  176. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  177. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  178. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  179. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  180. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  181. “No Price is too low for a bear or too high for a bull.” — Anonymous
  182. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  183. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  184. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  185. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  186. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  187. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  188. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  189. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  190. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  191. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  192. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  193. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  194. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  195. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  196. “Know what you own, and know why you own it.” – Peter Lynch
  197. “Liquidity is only there when you don’t need it.” -Old Proverb
  198. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  199. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  200. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  201. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  202. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  203. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  204. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  205. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  206. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  207. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  208. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  209. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  210. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  211. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  212. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  213. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  214. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  215. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  216. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  217. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  218. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  219. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: